The Role of Calcineurin Inhibitors in Lupus Nephritis In the U.S, lupus nephritis affects approximately 40–50% of patients with systemic lupus erythematosus (SLE), contributing significantly to the morbidity and mortality of the affected individuals (1). However, significant https://t.co/JBz0gQeJUr

Osteoporosis: Thinking outside the box Osteoporosis care keeps evolving. We have newer agents, newer sequencing strategies, and an increasing number of patients asking for “less medicinal” options that go beyond a prescription. https://t.co/1mGIrx8tm5 https://t.co/QVjeIwXESr

• Osteoporosis: Thinking outside the box | RheumNow

Poor sleep increases risk of #RA. English Longitudinal Study of Ageing. RA risk was signif. higher in those with moderate sleep quality (SQ) (HR 1.23) or poor SQ (HR 1.50), cmpared to good SQ. Partly mediated by depression https://t.co/kTbCUHeIGi https://t.co/6CD5tsKDdA

• https://buff.ly/Sw0COSw

Physician Assistant Workforce Grew 28% in USA (2020 To 2024), reaching 189,188 PAs; increased in every state (lease in Alaska 10%, most in SCarolina 48%,(to 2,984 in 2024). In 2024, there were 55.6 PAs/100,000 population https://t.co/VdXP3aM3ga https://t.co/qin2zfuUZe

• https://buff.ly/QhU4u8i

Muscular strength is a resilience marker relevant to function. A prospective cohort study of 5472 women (mean 79 yrs), showed that greater muscular strength (grip strength, chair stand time) was assoc w/ lower mortality (HR 0.85- 0.67) https://t.co/HEO4r2cdmS https://t.co/Ada3Bnrt0Z

• Muscular Strength and Mortality in Women Aged 63 to 99 Years

Missed #RheumNowLive 2026? The full meeting is now available On Demand. ✔ 2 days of clinical updates ✔ Expert faculty panels ✔ Speaker slides ✔ Pre-learn modules Watch anytime for $250. Learn from the meeting that kicks off the year in rheumatology. 🔗 Access here: https://t.co/hAvw6a8GQ1

B cell Targeted CAR-T Therapy for Autoimmune Diseases The review by Qi Li and colleagues provides a comprehensive examination of the progression, clinical applications, challenges, and future directions of B-cell-targeted CAR-T therapy across multiple autoimmune conditions. https://t.co/b1SmrOBbBU

Hydroxychloroquine Lowers SLE and RA Hospitalizations A population-based study from British Columbia, Canada, shows that antimalarial adherence was associated with a lower risk of hospital admission in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus https://t.co/vsJDOh09ji

Observational study of 42 Mexican lupus nephritis pts on Immunosuppressives + Calcineurin Inhibitors (CNIs) @ 12 mos complete & partial responses seen in 26% & 36%, w/ signif reduction in proteinuria (2.89 vs 0.72 g/d, p < .001), & transient decrease in eGFR at 12 mo (109 vs 114) https://t.co/Het4GKaTmv

FDA has approved deucravacitinib (Sotyktu) the Treatment of Adults with Active Psoriatic Arthritis based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials. Sotyktu is the only tyrosine kinase 2 (TYK2) inhibitor to be approved for PsA https://t.co/8xBrgPfENH

DERM on RheumNow PODCAST (February 2026) The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, and other CTD skin disorders. dermatology drugs, biologics, JAKs - their use, efficacy, https://t.co/4ub0MeY9vF

IL-23i fails in GCA? Small RCT of 53 GCA pts (age 71 yrs; 60% new; 40% relapsing GCA) 35 given Guselkumab vs 18 on PBO. Wk 28 GC free remission in 40% vs 33% (P .64), also w/ similar flare rates (31% v 39%). results didnt supportguselkumab use in GCA. https://t.co/AMTmiDBc94 https://t.co/4AQe8HbwQp

• A phase 2, randomised, placebo-controlled study of guselkumab in adults with ne…

Diacerin, an IL-1β blocker, compared to placebo in a 262 pt RCT of knee pain, Knee #OA w/ inflammation. After 24 wks, 88% completed the trial & (vs PBO) diacerein did not improve knee pain (−19.9 vs −18.6 mm). 42% had AE/ GI Sxs were more w/ diacerein (42% vs 25% PBO https://t.co/P2d6IhFw2I

US Epidemiologic survey data from NHANES gout prevalence is incr. in RA pts vs controls (10.3% vs. 4.8%, P < 0.001), increasing trend over time. RA is as an independent risk factor for gout (OR: 2.67), strongest in SNRA. Evidence for the converse may not be as strong. https://t.co/hhRT9NCzVG